Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has been assigned a $190.00 price target by equities research analysts at Cowen and Company in a report released on Monday. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Cowen and Company’s price objective indicates a potential upside of 33.80% from the stock’s current price.

Other equities research analysts have also issued research reports about the stock. Leerink Swann upped their target price on shares of Jazz Pharmaceuticals PLC from $169.00 to $170.00 and gave the stock a “buy” rating in a report on Tuesday, July 4th. Janney Montgomery Scott upped their price objective on shares of Jazz Pharmaceuticals PLC from $138.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, July 4th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $176.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Tuesday, July 4th. Vetr raised shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $165.11 price objective for the company in a research report on Tuesday, June 27th. Finally, Royal Bank Of Canada set a $210.00 price objective on shares of Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research report on Tuesday, June 27th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have assigned a buy rating to the company’s stock. Jazz Pharmaceuticals PLC presently has a consensus rating of “Buy” and a consensus target price of $180.88.

Shares of Jazz Pharmaceuticals PLC (NASDAQ JAZZ) traded up 1.31% during trading on Monday, hitting $142.00. The stock had a trading volume of 400,548 shares. Jazz Pharmaceuticals PLC has a 1-year low of $95.80 and a 1-year high of $163.75. The firm has a 50-day moving average of $147.50 and a 200 day moving average of $151.39. The company has a market capitalization of $8.53 billion, a P/E ratio of 21.87 and a beta of 1.05.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.85 by ($0.13). Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The business had revenue of $394.39 million during the quarter, compared to analyst estimates of $410.83 million. During the same quarter in the prior year, the company earned $2.67 EPS. The company’s revenue was up 3.5% on a year-over-year basis. Equities research analysts predict that Jazz Pharmaceuticals PLC will post $10.88 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.americanbankingnews.com/2017/10/24/jazz-pharmaceuticals-plc-jazz-given-a-190-00-price-target-by-cowen-and-company-analysts-2.html.

In related news, SVP Paul Treacy sold 1,304 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $143.32, for a total value of $186,889.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul L. Berns sold 662 shares of the firm’s stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $142.37, for a total transaction of $94,248.94. Following the completion of the transaction, the director now directly owns 6,599 shares of the company’s stock, valued at $939,499.63. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 4,517 shares of company stock valued at $665,623. 4.30% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in JAZZ. Parametric Portfolio Associates LLC boosted its holdings in Jazz Pharmaceuticals PLC by 23.6% in the 1st quarter. Parametric Portfolio Associates LLC now owns 28,466 shares of the specialty pharmaceutical company’s stock worth $4,131,000 after buying an additional 5,427 shares during the period. Envestnet Asset Management Inc. lifted its stake in Jazz Pharmaceuticals PLC by 43.0% in the 1st quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock worth $141,000 after purchasing an additional 295 shares in the last quarter. Victory Capital Management Inc. lifted its stake in Jazz Pharmaceuticals PLC by 1,074.9% in the 1st quarter. Victory Capital Management Inc. now owns 3,278 shares of the specialty pharmaceutical company’s stock worth $476,000 after purchasing an additional 2,999 shares in the last quarter. Alliancebernstein L.P. lifted its stake in Jazz Pharmaceuticals PLC by 19.4% in the 1st quarter. Alliancebernstein L.P. now owns 4,211 shares of the specialty pharmaceutical company’s stock worth $611,000 after purchasing an additional 684 shares in the last quarter. Finally, United Services Automobile Association purchased a new stake in Jazz Pharmaceuticals PLC in the 1st quarter worth approximately $697,000. 87.91% of the stock is owned by institutional investors.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.